The world’s leading animal health companies are digging deeper into the heart of the KC Animal Health Corridor at Hunt Midwest’s SubTropolis, the world’s largest underground business complex.

Ceva Animal Health, Vedco, and Virbac operate a combined 350,000 square feet of distribution space for their leading veterinary pharmaceuticals and animal health care products at SubTropolis, located in the center of the business corridor now responsible for 50% of the global sales in the animal health industry.

Both Ceva and Vedco recently extended their leases in SubTropolis, where the underground environment offers secure, scalable, and energy efficient space with unbeatable cost savings and premier logistics advantages. Both companies have worked closely with Hunt Midwest to grow and streamline their operations underground to better support their businesses nationwide.

“We’ve leased commercial space from Hunt Midwest SubTropolis for several years and have been consistently impressed with their professionalism, responsiveness, and commitment to maintaining a high-quality property environment,” said Vedco General Manager Craig Campbell. “Our experience with them as our commercial landlord has been excellent. They are proactive with maintenance, transparent in their communication, and genuinely invested in supporting our success … We see them not just as a landlord, but as a partner. They listen to our feedback, are open to collaboration, and work hard to create a positive business community throughout the Subtropolis network.”

Because the entire SubTropolis complex is considered a single USDA-approved storage facility, the review and approval process for opening new regulated storage space underground is dramatically simplified and there are no weather delays 150 feet underground. The natural properties of SubTropolis’ limestone also create a stable 68- to 70-degree environment year-round, allowing companies to meet strict USP-defined “Controlled Room Temperature” ranges with substantially less upfront capital costs of a traditional surface facility and meaningful cost savings in perpetuity. One analysis of a temperature-controlled, 150,000-square-foot bioscience distribution facility found savings of more than $125,000 annually operating in SubTropolis versus a traditional surface property.

SubTropolis also offers animal health significantly more security protection than traditional surface industrial parks with on-site 24/7 armed security, access control to the complex, and on-site security system monitoring. Thanks to Hunt Midwest’s decades-long partnerships with the federal government, SubTropolis also boasts a GSA Level IV Secured Facility rating to meet the most stringent security requirements.

With unmatched expansion flexibility, key environmental advantages, and rock-solid security, it’s easy to see why the KC Animal Health Corridor is heading underground to SubTropolis.

Ryan Tompkins
Senior Director, Sales & Leasing
Hunt Midwest

KANSAS CITY, Missouri, JAN 17, 2026 / — Animalytix LLC, the leading provider of market insight and reference services for the veterinary and animal health sectors in the United States and Canada, today announced ahead of the VMX 2026 Conference their plans to introduce a new marketplace services platform for veterinarians. When introduced later this year, VetGetRx.com will provide veterinary practitioners and their vendor partners a “Best-in-Class” marketplace alternative for veterinary practice owners, managers, and procurement specialists to shop for, compare, and purchase the key products needed to support their daily practice operations.

The new platform is a cooperative effort supported by Covetrus, Midwest Veterinary Supply, MWI Animal Health, and Patterson Veterinary Supply, in collaboration with DVMetrics Marketplace LLC, a newly created subsidiary of Animalytix LLC. Animalytix LLC, and its subsidiary DVMetrics & Services LLC, currently provide a variety of market insight and reference services, including the Compendium of Veterinary Products, the North American Companion Animal Formulary, SDSL Autobinder OSHA compliance documentation, and the VetDocs™ Pet Medication Information library to the veterinary profession, animal health manufacturers, and distributors.

Since 2019, Animalytix and DVMetrics have also provided a variety of compliance reporting services in support of efforts by Group Purchasing Organizations, independent veterinary practitioners, and their vendor partners to more closely align their business objectives. The most widely used of these services is ProgramTRAXSM which is currently utilized by thousands of hospitals to deliver cost savings and other eNiciencies to US practice owners.

Nick Meurrier, General Manager of DVMetrics MarketplaceSM, says the company is focused exclusively on its mission to deliver a free, fair, and secure marketplace for veterinarians, enabling distributors and manufacturers to aggressively and transparently compete for the sale of pharmaceuticals, vaccines, nutraceuticals, pet nutrition, hospital supplies, and other goods routinely purchased by veterinary hospitals and practices. Meurrier noted “The business environment for veterinary practices is very challenging at the moment and practice owners and managers are looking for every opportunity to drive cost savings and operational eNiciency to enhance value for their clients. We look forward to delivering both as part of the VetGetRxSM user experience as we work together with our distributor partners to bring this new platform to the market.”

When launched, VetGetRx.com will offer a full array of veterinary, human labeled, and compounded pharmaceuticals along with vaccines, nutraceuticals, medical supplies, and pet nutrition products from a broad assortment of participating distributors and manufacturers.

Jeff Baker, Director of Business Development for DVMetrics Marketplace, will be leading the company’s outreach to corporate hospitals, group purchasing organizations, and those interested in marketing their goods on the platform.

Those interested in learning more should visit the company’s website @ VetGetRx.com to subscribe for news and updates on the platform.

FOR IMMEDIATE RELEASE

Wednesday 14th January, 2026 – Hale Animal Health, a New Zealand-based veterinary pharmaceutical company, today announced the successful completion of its latest capital raise, securing NZD $4 million from existing shareholders and welcoming Arrow Ventures as a new strategic investor.

This funding marks a significant milestone for Hale Animal Health as the company advances its mission to improve the quality of life for companion animals through science and innovation. The capital will be used to propel Hale into the next phase of development and trials following the completion of a large-scale clinical trial involving 112 dogs across New Zealand.
The recently completed trial focused on Hale’s lead product, a cannabinoid-based medicine designed to treat dogs suffering from osteoarthritis (OA), a condition that affects a significant proportion of the canine population. OA can cause chronic pain and reduced mobility, and while traditional medicines exist, many dogs cannot tolerate them due to side effects or lack of efficacy. Hale’s product aims to provide an alternative that delivers pain relief comparable to existing treatments but with a superior safety profile, addressing a critical unmet need in veterinary medicine.

“This capital raise is a pivotal moment for Hale” said Leila de Koster, CEO of Hale Animal Health. “With the support of our existing shareholders and the addition of Arrow Ventures, we are well positioned to build on the success of our latest clinical trial and move forward with the next stage of development. Our goal is to deliver evidence-based therapies that address underserved needs in veterinary medicine, and this investment brings us closer to achieving that vision.”

Troy Merry, Chief Operations Officer of Arrow Ventures, added: “We are excited to partner with Hale Animal Health as they lead the way in developing innovative, clinically validated solutions for companion animals. Their commitment to rigorous research and regulatory excellence aligns perfectly with our investment philosophy, and we look forward to supporting their growth and impact in the veterinary pharmaceutical space.”

With these milestones achieved, Hale Animal Health is now focused on advancing its pipeline of therapies, including one of the world’s first clinically trialled and registered cannabinoid-based medicines for pets.

–ENDS–

For media enquiries, please contact:
Leila de Koster
CEO
Hale Animal Health
leila@haleanimal.co.nz
02041223412
www.haleanimal.co.nz

About Hale

Hale Animal Health is a New Zealand-based veterinary pharmaceutical company committed to improving the quality of life for companion animals through innovation and science. Headquartered in Auckland New Zealand, Hale is developing one of the world’s first clinically trialled and registered cannabinoid-based medicines for pets. With a focus on rigorous research, regulatory excellence, and animal wellbeing, Hale is building a pipeline of evidence-based therapies to address some of the most pressing needs in veterinary medicine.

Media Contact:
Paula Flavin
Project Marketing Manager
D: 816-912-2000
Email: info@felixvetus.com

Felixvet Receives FDA Approval for Meloxicam Oral Suspension

Kansas City, MO — December 18, 2025 — Felixvet Inc. is proud to expand its growing line of FDA-approved veterinary pharmaceuticals with the approval of Meloxicam Oral Suspension, a prescription NSAID formulated to manage pain and inflammation caused by osteoarthritis in dogs. With an emphasis on therapeutic value and affordability, Felixvet is helping meet the daily clinical needs of veterinarians and the long-term care needs of aging pets.

“Pain relief is essential to quality of life, especially for aging pets,” said Vince Palasota, President of North America at Felixvet. “With the approval of Meloxicam Oral Suspension, we’re providing veterinarians and pet owners with a safe, trusted treatment option backed by rigorous FDA standards.”

Meloxicam Oral Suspension is a prescription NSAID that offers effective relief from osteoarthritis symptoms such as stiffness, decreased mobility and joint pain. While not a cure, the medication helps reduce inflammation and improve overall comfort and activity levels in affected dogs. Clinical results may be seen within days, and daily administration can significantly improve a pet’s quality of life.

The oral suspension is easy to administer, particularly for small dogs, and comes in a 1.5 mg/mL concentration. It includes a dosing syringe for accurate measurement and can be mixed with food or administered directly, depending on the dog’s weight and veterinarian guidance.

“Pet owners are seeking convenient and dependable options to manage chronic pain,” Palasota added. “Meloxicam Oral Suspension delivers on both counts and represents another important step in our expanding portfolio of generic veterinary pharmaceuticals.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, email info@felixvetus.com.

About Felixvet:

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.